ImmunityBio advances NMIBC and NSCLC treatments with promising trial data and plans 2025 FDA submissions for innovative ...
Zacks.com on MSN3d
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer DrugJohnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback